Rani Therapeutics Holdings, Inc.

NasdaqGM RANI

Rani Therapeutics Holdings, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -9.55

Rani Therapeutics Holdings, Inc. Interest Coverage Ratio is -9.55 for the Trailing 12 Months (TTM) ending September 30, 2024, a 35.43% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Rani Therapeutics Holdings, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -14.80.
Rani Therapeutics Holdings, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -81.82.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGM: RANI

Rani Therapeutics Holdings, Inc.

CEO	Mr. Talat Imran
IPO Date	July 30, 2021
Location	United States
Headquarters	2051 Ringwood Avenue
Employees	140
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Key trends

Past 5 years